China SXT Pharmaceuticals, Inc. (SXTC) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - Specialty & Generic industria. La empresa tiene su sede en Taizhou, China. El CEO actual es Feng Zhou.
SXTC tiene fecha de IPO 2019-01-04, 75 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $1.59M.
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.
